MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MeiraGTx Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.45+0.17 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $886.46M
- P/E (TTM)
- 13.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
-130.2%+271.7 pts over 5 years
Net margin
-140.3%+232.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +144.6% | +72.3% | +39.2% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -27.0% | -368.2% | |
| Return on assets | – | -16.9% | -44.4% | |
| Current ratio | – | 5.03 | 0.75 | |
| Debt to equity | – | – | -8.58 | |
| Net debt to EBITDA | – | – | 0.17× | |
| Interest coverage | – | -450.0× | -8.7× | |
| Capex to revenue | – | 134.4% | 4.7% | |
| Diluted shares | – | 38M | 80M |
Where the cash went
Fiscal 2021 to 2025, five years combined
MeiraGTx generated $339.85M from operations and spent $120.27M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$339.85M
Used
$120.27M
Capital expenditure$120.27M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-140.3%
×Asset turnover0.32×
×Equity multiplier8.29×
=Return on equity, FY2025-368.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -140.3% | 0.32× | 8.29× | -368.2% |
| FY2024 | -444.1% | 0.11× | 2.90× | -143.5% |
| FY2023 | -599.5% | 0.04× | 2.52× | -65.7% |
| FY2022 | -814.2% | 0.05× | 2.11× | -85.5% |
| FY2021 | -211.0% | 0.11× | 1.61× | -37.5% |
| FY2020 | -372.6% | 0.05× | 1.60× | -27.0% |
| FY2019 | -411.9% | 0.06× | 1.55× | -40.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$114.20M
- Cash generatingOperating cash flow above zero-$46.36M
- Return on assets improvedROA up on the prior year-45.2% → -42.3%
- Earnings backed by cashOperating cash flow above net income-$46.36M vs -$114.20M
- Less leverageLong-term debt to assets fell27.1% → 20.3%
- Better liquidityCurrent ratio rose2.03 → 0.75
- No dilutionShare count did not rise70M → 80M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.10 → 0.30